Subscribe to Entrepreneur for $5
Subscribe

Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics

Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.

By
This story originally appeared on Zacks

Amgen Inc. AMGN announced that it has entered into a research collaboration agreement with Massachusetts-based private biotech Generate Biomedicines to discover and develop protein therapeutics for five clinical targets in several therapeutic areas and multiple modalities.

- Zacks

Under the deal, Generate’s machine-learning-enabled technology generative biology platform will be leveraged to discover and create novel protein sequences with optimal therapeutic properties.

Per the deal for the five initial programs, Amgen will make an upfront payment of $50 million to Generate Biomedicines. Amgen will pay around $370 million in future milestones as well as royalties up to low double digits for each of the five programs. Amgen will have the option to nominate up to five more programs at additional cost.

Shares of Amgen have lost 5.6% in the past year compared with the industry’s decline of 30%.

Zacks Investment ResearchImage Source: Zacks Investment Research

Amgen remains focused on driving growth and boosting its pipeline through deals and acquisitions.

Amgen entered into an agreement with Japanese pharmaceutical company, Kyowa Kirin Co, to jointly develop and commercialize KHK4083 for the treatment of atopic dermatitis (“AD”) in June 2021. KHK4083 is a potential first-in-class anti-OX40 fully-human monoclonal antibody being developed by Kyowa Kirin for AD and other potential autoimmune diseases.

In October 2021, Amgen signed a strategic collaboration with Neumora Therapeutics to advance neuroscience discovery. The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities to advance innovative medicines for brain disease.

Also, in 2021, Amgen acquired Five Prime Therapeutics, which added late-stage cancer candidate bemarituzumab to Amgen’s pipeline. Amgen completed the acquisition of small private cancer biotech Teneobio in October 2021. The acquisition included Teneobio's proprietary bispecific and multispecific antibody technologies. The acquisition added TNB-585, a phase I bispecific T cell-engager, for the treatment of metastatic castrate-resistant prostate cancer to Amgen’s pipeline.

Zacks Rank & Stocks to Consider

Amgen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the drug/biotech sector include PaciraBioSciences, Inc. PCRX, Precision BioSciences, Inc. DTIL and AnaptysBio, Inc. ANAB, all sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Pacira’s earnings estimates have been revised 5.7% upward for 2022 over the past 60 days.

Pacira’s earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.

Precision BioSciences’ loss per share estimates have narrowed 20.1% for 2022, over the past 60 days.

Precision BioSciences’ earnings surpassed estimates in each of the trailing four quarters.

AnaptysBio’s loss per share estimates have narrowed 1.6% for 2022, over the past 60 days. The stock has rallied 33.4% in the past year.

AnaptysBio’s earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.



Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Amgen Inc. (AMGN): Free Stock Analysis Report

 

Pacira BioSciences, Inc. (PCRX): Free Stock Analysis Report

 

AnaptysBio, Inc. (ANAB): Free Stock Analysis Report

 

Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research